Core Laboratories N.V. (CLB) Stock Forecast
CLB analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.67 / 5 from 3 analysts
- Price target
- $15.00 average of analyst targets
- Upside to target
- +50.0% from the latest close
- Next earnings
- October 28, 2026 EPS estimate $0.17
- 52-week range
- $9.70 – $19.67
CLB analyst ratings
3 analystsNumber of analysts at each rating.
CLB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CLB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.16 | $0.15 | $0.17 | $0.22 | −27.3% | 3 |
| Current fiscal year (2026) | $0.51 | $0.49 | $0.52 | $0.75 | −32.4% | 3 |
| Next fiscal year (2027) | $0.69 | $0.54 | $0.79 | $0.51 | +36.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CLB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $132.1M | $131.8M | $132.6M | −1.8% | 3 |
| Current fiscal year (2026) | $511.9M | $508.7M | $515.5M | −2.8% | 3 |
| Next fiscal year (2027) | $524.8M | $507.9M | $540.7M | +2.5% | 3 |
CLB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CLB revenue: reported and forecast
CLB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.18 | $0.15 | $0.15 | $0.15 | $0.16 | −11.1% | 1 up · 0 down |
| Current fiscal year (2026) | $0.54 | $0.43 | $0.46 | $0.46 | $0.51 | −6.2% | 1 up · 0 down |
| Next fiscal year (2027) | $0.85 | $0.68 | $0.70 | $0.70 | $0.69 | −19.3% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CLB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CLB beat in 10 of 12.
What analysts expect from CLB
3 analysts cover Core Laboratories; their consensus rating is buy (3.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $15.00, 50.0% above the latest close of $10.00. Analysts expect earnings of $0.51 per share for 2026, −32.4% from a year earlier. For 2027 the average estimate is $0.69 per share on revenue of $524.8 million. Core Laboratories beat the EPS estimate in 10 of the last 12 quarters.
Related: CLB income statement, CLB key metrics, CLB chart. See the CLB stock overview for the latest quote and news.
CLB forecast FAQ
What is Core Laboratories's price target?
The average analyst price target for Core Laboratories is $15.00, 50.0% above the latest close of $10.00.
Is Core Laboratories a buy, hold or sell?
Of 3 analysts covering Core Laboratories, 1 rate it a strong buy, 1 a buy, 0 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Core Laboratories's EPS forecast?
Analysts forecast $0.51 per share for 2026 (range $0.49 to $0.52); for 2027 the estimate is $0.69.
What is Core Laboratories's revenue forecast?
The average revenue estimate for 2026 is $511.9 million, growth of −2.8%; for 2027 it is $524.8 million.
When does Core Laboratories report earnings?
Core Laboratories is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 after the market closes; the EPS estimate is $0.17.
Does Core Laboratories usually beat earnings estimates?
Core Laboratories reported EPS at or above the analyst estimate in 10 of the last 12 quarters.